Board Member
Prothena Corp Public Ltd Co (PRTA)Equibles does not estimate personal net worth.
Get an email with a short summary when Prothena Corp Public Ltd Co publishes a filing, an earnings call transcript or a press release.
Get PRTA alertsGene Kinney is recorded as Board Member and CEO at Prothena Corp Public Ltd Co (PRTA). The newest filing on record that lists Gene Kinney as Board Member at Prothena Corp Public Ltd Co (PRTA) is dated October 7, 2025. The newest filing on record that lists Gene Kinney as CEO at Prothena Corp Public Ltd Co (PRTA) is dated March 31, 2021. The proxy statement of Prothena Corp Public Ltd Co reports total compensation of $3,213,354 for Gene Kinney in fiscal 2019, including a base salary of $538,125. Disclosed compensation is on record for 3 fiscal years. Gene Kinney has spoken on 6 earnings calls and 1 other investor event across 1 company, most recently for Prothena Corp Public Ltd Co on September 16, 2026. Prothena Corp Public Ltd Co is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Prothena Corp Public Ltd Co includes Lars G. Ekman (Chairman and Board Member), Brandon S. Smith (COO and Board Member), Brandon Smith (Board Member) and 7 others.
“It's always great to be here and to have a chance to discuss the pipeline in the company. I think Prothena today is a very rich company in terms of its pipeline.”
“In 2025, we saw significant progress with our clinical pipeline where two of our partner programs, Pracinizumab and Gramatog, advanced into phase three clinical trials.”
“Our mission at Prathina is to create transformational therapies addressing significant unmet medical needs for the millions of patients and their loved ones that are affected by devastating life-threatening diseases caused by protein dysregulation.”
“Thank you, Mark, and thank you all for joining us today to review our 2023 financial results and business highlights. Let’s begin on Slide 5.”
“Thank you, Eric, and thank you all for joining us today to review our 2022 financial results and business highlights. We're excited to share Prothena's major achievements in 2022 and how we are advancing a portfolio of drug candidates targeting both neurodegenerative and rare peripheral amyloid diseases.”
Start not stated–present
Last confirmed October 7, 2025
Start not stated–present
Last confirmed March 31, 2021
Biotechnology · Healthcare
Board Member, CEO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2019 | Prothena Corp Public Ltd Co (PRTA) | President and Chief Executive Officer | $538,125 | $3,213,354 |
| 2018 | Prothena Corp Public Ltd Co (PRTA) | President and Chief Executive Officer | $525,000 | $11,396,769 |
| 2017 | Prothena Corp Public Ltd Co (PRTA) | President and Chief Executive Officer | $520,833 | $5,148,245 |
